BNP Paribas Financial Markets Reduces Stock Holdings in Twist Bioscience Co. (NASDAQ:TWST)

BNP Paribas Financial Markets cut its position in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 20.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 127,474 shares of the company's stock after selling 32,777 shares during the quarter. BNP Paribas Financial Markets owned 0.22% of Twist Bioscience worth $4,699,000 as of its most recent SEC filing.

A number of other hedge funds have also recently made changes to their positions in the company. Federated Hermes Inc. acquired a new stake in Twist Bioscience during the 3rd quarter valued at approximately $29,000. EdgeRock Capital LLC bought a new position in Twist Bioscience during the fourth quarter worth $30,000. Allspring Global Investments Holdings LLC raised its stake in Twist Bioscience by 51.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company's stock worth $70,000 after buying an additional 1,179 shares during the last quarter. International Assets Investment Management LLC boosted its position in Twist Bioscience by 3,519.8% during the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company's stock valued at $148,000 after acquiring an additional 3,907 shares during the last quarter. Finally, Mesirow Financial Investment Management Inc. bought a new stake in Twist Bioscience during the third quarter valued at $223,000.

Twist Bioscience Stock Down 1.8 %

TWST traded down $0.83 during trading on Tuesday, hitting $44.04. 701,771 shares of the company's stock were exchanged, compared to its average volume of 999,365. The stock has a market cap of $2.56 billion, a P/E ratio of -13.11 and a beta of 1.64. Twist Bioscience Co. has a fifty-two week low of $13.11 and a fifty-two week high of $50.50. The business's 50 day moving average is $35.65 and its two-hundred day moving average is $33.58.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The company reported ($0.79) EPS for the quarter, topping the consensus estimate of ($0.84) by $0.05. The firm had revenue of $75.30 million during the quarter, compared to the consensus estimate of $70.70 million. Twist Bioscience had a negative return on equity of 31.61% and a negative net margin of 69.24%. The company's quarterly revenue was up 25.1% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.06) earnings per share. On average, sell-side analysts forecast that Twist Bioscience Co. will post -3.12 earnings per share for the current year.

Insiders Place Their Bets

In other Twist Bioscience news, SVP Paula Green sold 910 shares of Twist Bioscience stock in a transaction that occurred on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total transaction of $33,788.30. Following the transaction, the senior vice president now owns 91,511 shares of the company's stock, valued at approximately $3,397,803.43. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, SVP Paula Green sold 910 shares of the business's stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $33,788.30. Following the transaction, the senior vice president now directly owns 91,511 shares of the company's stock, valued at approximately $3,397,803.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider William Banyai sold 798 shares of the stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $37.13, for a total transaction of $29,629.74. Following the transaction, the insider now owns 345,188 shares of the company's stock, valued at approximately $12,816,830.44. The disclosure for this sale can be found here. Insiders have sold 17,415 shares of company stock valued at $614,504 in the last three months. 3.92% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

TWST has been the topic of a number of recent analyst reports. Scotiabank boosted their price objective on Twist Bioscience from $43.00 to $48.00 and gave the company a "sector outperform" rating in a research note on Monday, May 6th. Robert W. Baird raised their price objective on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an "outperform" rating in a research report on Friday, May 3rd. Barclays lifted their price objective on shares of Twist Bioscience from $40.00 to $45.00 and gave the company an "overweight" rating in a research note on Friday, May 3rd. Finally, Evercore ISI increased their target price on shares of Twist Bioscience from $46.00 to $50.00 and gave the stock an "outperform" rating in a research note on Friday, May 3rd. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $42.50.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.